Eli Lilly and Company
Rapid-acting insulin compositions
Last updated:
Abstract:
The invention is a pharmaceutical composition of human insulin or insulin analog that includes citrate, treprostinil and stabilizing agents, that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products and that is stable for commercial use.
Status:
Grant
Type:
Utility
Filling date:
11 Jan 2018
Issue date:
23 Feb 2021